🇺🇸 FDA
Patent

US 11384153

Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 11384153 (Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K2239/48, A61K40/11